P311: Strategic Insights into Evidence and Benefit-Risk Expectations of Health Authorities
Poster Presenter
Timothy Kline
Senior Director, Global Regulatory Affairs
Aadi Biosciences Inc. United States
Objectives
To identify regulatory decision drivers underlying FDA Complete Response Letters (CRLs) by analyzing public CRL data anonymized for product specific detail, with the goal of informing evidence generation and educating on potential future regulatory strategies across drug development programs
Method
Systematic review of CRLs and correlation by leveraging a reasoning algorithm. Deficiencies were qualitatively coded into regulatory strategy domains, including evidence adequacy, benefit–risk determination, study pre-specification, and population definition.
Results
A review of publicly available CRLs, grounded against Health Authority Guidance for Industry, original articles, and clinical practice revealed consistent regulatory themes that directly inform regulatory strategy. This series of anonymized case studies assesses CRLs that frequently cited failures to meet standards for “adequate and well-controlled” investigations, particularly when sponsors relied on externally controlled trials or real-world evidence as primary support for effectiveness. Sample key strategic gaps included lack of pre-specification, residual confounding, missing data, and misalignment between study design and regulatory guidance.
The fundamental requirement for a positive benefit–risk emphasizes the Agency’s expectation that sponsors clearly define a clinically identifiable population in whom benefits outweigh risks. When serious safety signals were present coupled with modest or inconsistent efficacy - especially when driven by post hoc subgroup analyses – these applications are consistently insufficient to support approval. FDA reviewers consistently highlighted uncertainty in treatment effect magnitude, durability, and clinical meaningfulness as central to negative regulatory outcomes.
A reasoning algorithm was leveraged for complex questions, such as identifying inconsistencies between CRLs and relevant Health Authority issued guidance to be answered. Multiple case studies exemplify that higher levels of risk necessitate greater certainty and robustness of benefit, reinforcing the strategic importance of early population selection, endpoint justification, and alignment with evolving regulatory guidance. Means to account for analytical and interpretative challenges were factored into the assessment to mitigate business logic shortfalls, temporal shifts, and gaps in data continuity.
Conclusion
CRLs offer actionable intelligence for regulatory strategy by revealing how evidentiary weaknesses translate into approval barriers. This analysis demonstrates that regulatory failure is often driven not by isolated data gaps, but by cumulative misalignment between development strategy, evidence generation, and regulatory expectations. This presents an opportunity for the regulatory professional (e.g. global regulatory lead) to educate and influence stakeholders without authority by leveraging credible facts that should gain traction with management.
Sponsors can apply these insights to strengthen regulatory strategy by prioritizing prespecified analyses, robust study designs for external controls, proactive benefit–risk framing, and early engagement with regulators on acceptable evidence standards. This approach of data collection, data cleaning, assessment, analysis, and application is straightforward affording a wide array of regulatory professionals an opportunity to apply these methodologies. A systematic review of CRLs can serve as a strategic planning tool to anticipate regulatory risk and improve the likelihood of approval.
